These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38561690)

  • 1. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    Sheng M; Sun R; Fu J; Lu G
    BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
    BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.
    Navarro-Núñez L; Pollitt AY; Lowe K; Latif A; Nash GB; Watson SP
    Thromb Haemost; 2015 May; 113(5):1109-20. PubMed ID: 25694214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.
    Bianchi R; Fischer E; Yuen D; Ernst E; Ochsenbein AM; Chen L; Otto VI; Detmar M
    J Biol Chem; 2014 Jul; 289(30):21016-27. PubMed ID: 24907275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2.
    Tamura S; Suzuki-Inoue K; Tsukiji N; Shirai T; Sasaki T; Osada M; Satoh K; Ozaki Y
    Blood; 2016 Mar; 127(13):1701-10. PubMed ID: 26796360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2.
    Herzog BH; Fu J; Wilson SJ; Hess PR; Sen A; McDaniel JM; Pan Y; Sheng M; Yago T; Silasi-Mansat R; McGee S; May F; Nieswandt B; Morris AJ; Lupu F; Coughlin SR; McEver RP; Chen H; Kahn ML; Xia L
    Nature; 2013 Oct; 502(7469):105-9. PubMed ID: 23995678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI.
    Watanabe N; Shinozaki Y; Ogiwara S; Miyagasako R; Sasaki A; Kato J; Suzuki Y; Fukunishi N; Okada Y; Saito T; Iida Y; Higashiseto M; Masuda H; Nagata E; Gotoh K; Amino M; Tsuji T; Morita S; Nakagawa Y; Hirayama N; Inokuchi S
    Thromb Haemost; 2024 Mar; 124(3):203-222. PubMed ID: 37967855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLEC-2 stimulates IGF-1 secretion from podoplanin-positive stromal cells and positively regulates erythropoiesis in mice.
    Otake S; Sasaki T; Shirai T; Tsukiji N; Tamura S; Takano K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2021 Jun; 19(6):1572-1584. PubMed ID: 33774924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.
    Suzuki-Inoue K; Osada M; Ozaki Y
    J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice.
    Shirai T; Inoue O; Tamura S; Tsukiji N; Sasaki T; Endo H; Satoh K; Osada M; Sato-Uchida H; Fujii H; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2017 Mar; 15(3):513-525. PubMed ID: 28028907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes.
    Tanaka K; Tanaka M; Watanabe N; Ito M; Pastan I; Koizumi M; Matsusaka T
    Sci Rep; 2022 Dec; 12(1):22356. PubMed ID: 36572741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells.
    Pollitt AY; Poulter NS; Gitz E; Navarro-Nuñez L; Wang YJ; Hughes CE; Thomas SG; Nieswandt B; Douglas MR; Owen DM; Jackson DG; Dustin ML; Watson SP
    J Biol Chem; 2014 Dec; 289(52):35695-710. PubMed ID: 25368330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
    Suzuki-Inoue K
    Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CLEC-2-dependent platelet subendothelial accumulation by flow disturbance contributes to atherogenesis in mice.
    Tang C; Wang L; Sheng Y; Zheng Z; Xie Z; Wu F; You T; Ren L; Xia L; Ruan C; Zhu L
    Theranostics; 2021; 11(20):9791-9804. PubMed ID: 34815786
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.